Abstract

Repeat expansions in FGF14 cause autosomal dominant late-onset cerebellar ataxia (SCA27B) with estimated pathogenic thresholds of 250 (incomplete penetrance) and 300 AAG repeats (full penetrance), but the sequence of pathogenic and non-pathogenic expansions remains unexplored. Here, we demonstrate that STRling and ExpansionHunter accurately detect FGF14 expansions from short-read genome data using outlier approaches. By combining long-range PCR and nanopore sequencing in 169 patients with cerebellar ataxia and 802 controls, we compare FGF14 expansion alleles, including interruptions and flanking regions. Uninterrupted AAG expansions are significantly enriched in patients with ataxia from a lower threshold (180–200 repeats) than previously reported based on expansion size alone. Conversely, AAGGAG hexameric expansions are equally frequent in patients and controls. Distinct 5’ flanking regions, interruptions and pre-repeat sequences correlate with repeat size. Furthermore, pure AAG (pathogenic) and AAGGAG (non-pathogenic) repeats form different secondary structures. Regardless of expansion size, SCA27B is a recognizable clinical entity characterized by frequent episodic ataxia and downbeat nystagmus, similar to the presentation observed in a family with a previously unreported nonsense variant (SCA27A). Overall, this study suggests that SCA27B is a major overlooked cause of adult-onset ataxia, accounting for 23–31% of unsolved patients. We strongly recommend re-evaluating pathogenic thresholds and integrating expansion sequencing into the molecular diagnostic process.

Repeat expansions in the FGF14 gene can cause late-onset cerebellar ataxia (SCA27B), however the defining features of pathogenic expansions remain uncertain. Here, the authors compare the sequence and structure of FGF14 repeat expansions in patients and controls, leading them to suggest a lower pathogenic threshold and emphasizing the importance of sequencing the full expansion for accurate interpretation.

Details

Title
Identification and characterisation of pathogenic and non-pathogenic FGF14 repeat expansions
Author
Mohren, Lars 1   VIAFID ORCID Logo  ; Erdlenbruch, Friedrich 2   VIAFID ORCID Logo  ; Leitão, Elsa 1   VIAFID ORCID Logo  ; Kilpert, Fabian 1   VIAFID ORCID Logo  ; Hönes, G. Sebastian 3   VIAFID ORCID Logo  ; Kaya, Sabine 1 ; Schröder, Christopher 1   VIAFID ORCID Logo  ; Thieme, Andreas 2   VIAFID ORCID Logo  ; Sturm, Marc 4   VIAFID ORCID Logo  ; Park, Joohyun 4 ; Schlüter, Agatha 5 ; Ruiz, Montserrat 5   VIAFID ORCID Logo  ; Morales de la Prida, Moisés 6   VIAFID ORCID Logo  ; Casasnovas, Carlos 7   VIAFID ORCID Logo  ; Becker, Kerstin 8   VIAFID ORCID Logo  ; Roggenbuck, Ulla 9 ; Pechlivanis, Sonali 10 ; Kaiser, Frank J. 11 ; Synofzik, Matthis 12   VIAFID ORCID Logo  ; Wirth, Thomas 13   VIAFID ORCID Logo  ; Anheim, Mathieu 13 ; Haack, Tobias B. 14   VIAFID ORCID Logo  ; Lockhart, Paul J. 15   VIAFID ORCID Logo  ; Jöckel, Karl-Heinz 9 ; Pujol, Aurora 16   VIAFID ORCID Logo  ; Klebe, Stephan 2 ; Timmann, Dagmar 2 ; Depienne, Christel 1   VIAFID ORCID Logo 

 University Duisburg-Essen, Institute of Human Genetics, University Hospital Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445) 
 University Duisburg-Essen, Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445) 
 University of Duisburg-Essen, Department of Endocrinology, Diabetes and Metabolism, University Hospital Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445) 
 University of Tübingen, Institute of Medical Genetics and Applied Genomics, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447) 
 Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); ISCIII, CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185) 
 Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); Bellvitge University Hospital, Neuromuscular Unit, Neurology Department, Barcelona, Spain (GRID:grid.411129.e) (ISNI:0000 0000 8836 0780) 
 Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); ISCIII, CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185); Bellvitge University Hospital, Neuromuscular Unit, Neurology Department, Barcelona, Spain (GRID:grid.411129.e) (ISNI:0000 0000 8836 0780) 
 Faculty of Medicine and University Hospital Cologne, Cologne Center for Genomics (CCG), University of Cologne, Cologne, Germany (GRID:grid.411097.a) (ISNI:0000 0000 8852 305X) 
 University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445) 
10  University of Duisburg-Essen, Institute for Medical Informatics, Biometry and Epidemiology, University Hospital Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445); German Research Center for Environmental Health, Institute of Asthma and Allergy Prevention, Helmholtz Zentrum München, Neuherberg, Germany (GRID:grid.4567.0) (ISNI:0000 0004 0483 2525) 
11  University Duisburg-Essen, Institute of Human Genetics, University Hospital Essen, Essen, Germany (GRID:grid.5718.b) (ISNI:0000 0001 2187 5445); Universitätsklinikum Essen, Essener Zentrum für Seltene Erkrankungen (EZSE), Essen, Germany (GRID:grid.410718.b) (ISNI:0000 0001 0262 7331) 
12  Center for Neurology & Hertie Institute for Clinical Brain Research Tübingen, Division Translational Genomics of Neurodegenerative Diseases, Tübingen, Germany (GRID:grid.428620.a); German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany (GRID:grid.424247.3) (ISNI:0000 0004 0438 0426) 
13  Hôpital de Hautepierre, Service de Neurologie, Département de Neurologie, Hôpitaux Universitaires de Strasbourg, Strasbourg, France (GRID:grid.412201.4) (ISNI:0000 0004 0593 6932); INSERM-U964/CNRS-UMR7104/Université de Strasbourg, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France (GRID:grid.420255.4) (ISNI:0000 0004 0638 2716); Université de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), Strasbourg, France (GRID:grid.11843.3f) (ISNI:0000 0001 2157 9291) 
14  University of Tübingen, Institute of Medical Genetics and Applied Genomics, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447); University of Tübingen, Centre for Rare Diseases, Tübingen, Germany (GRID:grid.10392.39) (ISNI:0000 0001 2190 1447) 
15  The University of Melbourne, Bruce Lefroy Centre, Murdoch Children’s Research Institute; Department of Paediatrics, Parkville, Australia (GRID:grid.1008.9) (ISNI:0000 0001 2179 088X) 
16  Bellvitge Biomedical Research Institute (IDIBELL), Neurometabolic Diseases Laboratory, Barcelona, Spain (GRID:grid.418284.3) (ISNI:0000 0004 0427 2257); ISCIII, CIBERER, Centro de Investigación Biomédica en Red de Enfermedades Raras, Madrid, Spain (GRID:grid.452372.5) (ISNI:0000 0004 1791 1185); Catalan Institution of Research and Advanced Studies (ICREA), Barcelona, Spain (GRID:grid.425902.8) (ISNI:0000 0000 9601 989X) 
Pages
7665
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3100357214
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.